[go: up one dir, main page]

SG10201609933WA - New therapy for transthyretin-associated amyloidosis - Google Patents

New therapy for transthyretin-associated amyloidosis

Info

Publication number
SG10201609933WA
SG10201609933WA SG10201609933WA SG10201609933WA SG10201609933WA SG 10201609933W A SG10201609933W A SG 10201609933WA SG 10201609933W A SG10201609933W A SG 10201609933WA SG 10201609933W A SG10201609933W A SG 10201609933WA SG 10201609933W A SG10201609933W A SG 10201609933WA
Authority
SG
Singapore
Prior art keywords
transthyretin
new therapy
associated amyloidosis
amyloidosis
therapy
Prior art date
Application number
SG10201609933WA
Inventor
Casado Marc Centellas
Boronat Raul Insa
Bolano Nuria Reig
Batalla Nuria Gavalda
Original Assignee
Som Innovation Biotech S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47076222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201609933W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech S L filed Critical Som Innovation Biotech S L
Publication of SG10201609933WA publication Critical patent/SG10201609933WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/603Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10201609933WA 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis SG10201609933WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11382326 2011-10-24

Publications (1)

Publication Number Publication Date
SG10201609933WA true SG10201609933WA (en) 2017-02-27

Family

ID=47076222

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201609933WA SG10201609933WA (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis
SG11201401215VA SG11201401215VA (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201401215VA SG11201401215VA (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Country Status (19)

Country Link
US (5) US9610270B2 (en)
EP (1) EP2770988B1 (en)
JP (1) JP6068484B2 (en)
KR (1) KR102017354B1 (en)
CN (1) CN103889407B (en)
AU (2) AU2012327275B2 (en)
BR (1) BR112014009322B1 (en)
CA (1) CA2852808C (en)
CL (1) CL2014000893A1 (en)
CY (1) CY1118151T1 (en)
ES (1) ES2593038T3 (en)
IL (1) IL231907B (en)
MX (2) MX347784B (en)
PL (1) PL2770988T3 (en)
PT (1) PT2770988T (en)
RU (2) RU2623062C2 (en)
SG (2) SG10201609933WA (en)
WO (1) WO2013060668A1 (en)
ZA (1) ZA201402546B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102017354B1 (en) * 2011-10-24 2019-09-02 솜 이노베이션 바이오테크, 에스.엘. New therapy for transthyretin―associated amyloidosis
DK3185957T3 (en) * 2014-08-29 2022-08-29 Alnylam Pharmaceuticals Inc Patisiran for use in the treatment of transthyretin-mediated amyloidosis
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
KR20200131847A (en) * 2018-03-12 2020-11-24 코리노 테라퓨틱스 잉크 Combination therapy for TTR amyloidosis
EP3976017A4 (en) * 2019-05-31 2023-06-14 Plex Pharmaceuticals, Inc. Pharmacological agents for treating protein aggregation diseases of the eye
CN114324693B (en) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 Pretreatment method and detection method for determination of concentration of transthyretin (TTR) tetramer in blood
EP4601624A2 (en) * 2022-10-10 2025-08-20 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
FI20002044A0 (en) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Naphthalene derivatives which inhibit Comt enzymes
CA2440293C (en) 2001-03-15 2012-01-24 Proteotech, Inc. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
WO2004065614A2 (en) 2002-01-29 2004-08-05 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN1921856A (en) * 2004-02-20 2007-02-28 诺瓦提斯公司 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
KR20060124712A (en) 2004-02-20 2006-12-05 노파르티스 아게 DPP IV inhibitors to treat neurodegeneration and cognitive impairment
WO2005113523A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
CN101035541B (en) 2004-08-30 2012-05-30 柳署弘 Neuroprotective effect of solubilized UDCA in focal ischemic model
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (en) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
KR102017354B1 (en) * 2011-10-24 2019-09-02 솜 이노베이션 바이오테크, 에스.엘. New therapy for transthyretin―associated amyloidosis

Also Published As

Publication number Publication date
JP2014530842A (en) 2014-11-20
JP6068484B2 (en) 2017-01-25
MX347784B (en) 2017-05-12
US10449169B2 (en) 2019-10-22
BR112014009322B1 (en) 2022-05-10
AU2012327275A2 (en) 2014-04-17
CA2852808A1 (en) 2013-05-02
US9610270B2 (en) 2017-04-04
US20200390733A1 (en) 2020-12-17
KR20140090161A (en) 2014-07-16
US10045956B2 (en) 2018-08-14
US20140296188A1 (en) 2014-10-02
US20200138760A1 (en) 2020-05-07
MX385516B (en) 2025-03-18
AU2017202670B2 (en) 2019-06-06
ZA201402546B (en) 2015-07-29
MX2014004863A (en) 2014-05-27
BR112014009322A2 (en) 2017-04-18
EP2770988A1 (en) 2014-09-03
US20190091188A1 (en) 2019-03-28
AU2012327275B2 (en) 2017-03-02
IL231907A0 (en) 2014-05-28
HK1198432A1 (en) 2015-04-24
RU2747536C2 (en) 2021-05-06
ES2593038T3 (en) 2016-12-05
CN103889407A (en) 2014-06-25
PL2770988T3 (en) 2017-01-31
SG11201401215VA (en) 2014-08-28
CL2014000893A1 (en) 2014-09-05
RU2623062C2 (en) 2017-06-21
NZ623267A (en) 2015-11-27
CY1118151T1 (en) 2017-06-28
RU2017119539A3 (en) 2020-06-29
BR112014009322A8 (en) 2018-01-16
EP2770988B1 (en) 2016-07-20
WO2013060668A1 (en) 2013-05-02
CN103889407B (en) 2017-03-15
RU2014114930A (en) 2015-12-10
IL231907B (en) 2018-05-31
PT2770988T (en) 2016-09-05
AU2012327275A1 (en) 2014-04-17
RU2017119539A (en) 2018-11-09
US10786473B2 (en) 2020-09-29
CA2852808C (en) 2021-07-06
US11564899B2 (en) 2023-01-31
US20170304243A1 (en) 2017-10-26
AU2017202670A1 (en) 2017-05-11
KR102017354B1 (en) 2019-09-02

Similar Documents

Publication Publication Date Title
ZA201305897B (en) Combination therapy
PT2710018T (en) New compounds
GB201118652D0 (en) New compounds
GB201118654D0 (en) New compounds
HUE044576T2 (en) New compounds
GB201106803D0 (en) Sonodynamic therapy
ZA201400120B (en) Combination therapy
GB201114212D0 (en) Therapeutic agents
GB201119401D0 (en) Therapeutic agents
GB201106814D0 (en) New compounds
PT3034071T (en) New combination
ZA201402546B (en) New therapy for transthyretin-associated amyloidosis
ZA201400236B (en) Combination als therapy
PL2723330T3 (en) Vasoconstrictor-containing agent for combination therapy
EP2771012A4 (en) New compounds
ZA201502595B (en) Therapeutic methods
EP2701744A4 (en) Combination therapy
SG11201402226PA (en) Therapeutic agent for arthrosis
GB201206306D0 (en) Therapeutic apparatus
GB201102913D0 (en) Novel therapeutic
GB201102289D0 (en) New use
GB201114226D0 (en) Combination therapy
GB201120096D0 (en) Novel therapy
GB201110895D0 (en) Therapeutic use
GB201115558D0 (en) Therapeutic agents